 Randomized comparison ceftriaxone cefotaxime Lyme neuroborreliosis prospective open trial patients Lyme neuroborreliosis treatment ceftriaxone iv cefotaxime iv patients eligible analysis therapeutic efficacy Neurologic patients cefotaxime group patients ceftriaxone group treatment period follow-up examinations mean months patients asymptomatic patient Borrelia burgdorferi cerebrospinal fluid CSF months ceftriaxone therapy CSF antibiotic concentrations MIC level burgdorferi patients Patients Lyme neuroborreliosis treatment ceftriaxone cefotaxime patients symptomatic follow-up borreliae CSF patient prolongation therapy necessary